Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Baker, Jillian G ^a   Proudman, Richard G W ^a   Hill, Stephen J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; ARGININE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CIMATEROL; GLYCINE; ISOPRENALINE; METOPROLOL; NEBIVOLOL; NORADRENALIN; PINDOLOL; PROPRANOLOL; SERINE; TERBUTALINE; XAMOTEROL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENETIC POLYMORPHISM; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; SECOND MESSENGER; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HEART; HUMAN; METABOLISM; PATHOPHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHO CELLS; CRICETULUS; CYCLIC AMP; HEART; HUMANS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892641935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077582     Document Type: Article

References (59)

1. Shin J, Johnson JA (2007) Pharmacogenetics of beta-blockers. Pharmacotherapy 27(6): 874-87.
2. Johnson JA, Liggett SB (2011) Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 89(3): 366-78.
3. Heitz A, Schwartz J, Velly J (1983) Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding. Br J Pharmacol 80(4): 711-7.
4. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, et al. (1986) Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59(3): 297-309.
5. Brodde OE (2008) Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 117(1): 1-29.
6. Maqbool A, Hall AS, Ball SG, Balmforth AJ (1999) Common polymorphisms of beta1-adrenoceptor: identification and rapid screening assay. Lancet 353(9156): 897.
7. Börjesson M, Magnusson Y, Hjalmarson A, Andersson B (2000) A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 21(22): 1853-8.
8. Mason DA, Moore JD, Green SA, Liggett SB. (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 74(18): 12670-12674.
9. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, et al. (1999) Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. Mol Cell Cardiol 31(5): 1025-32.
10. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277(34): 30429-30435.
11. Rathz DA, Brown KM, Kramer LA, Liggett SB (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39(2): 155-60.
12. Magnusson Y, Levin MC, Eggertsen R, Nyström E, Mobini R, et al. (2005) Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78(3): 221- 231.
13. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, et al. (2008) Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 102(6): 726-732.
14. Nicoulina S, Shulman V, Shesternya P, Chernova A, Salmina A, et al.(2010) Association of ADRB1 gene polymorphism with atrial fibrillation. Genet Test Mol Biomarkers 14(2): 249-53.
15. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, et al. (2003) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74(1): 44-52.
16. Liu J, Liu ZQ, Yu BN, Xu FH, Mo W, et al. (2006) beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 80(1): 23-32.
17. Joseph SS, Lynham JA, Grace AA, Colledge WH, Kaumann AJ (2004) Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol 142: 51-6.
18. Huntgeburth M, La Rosée K, ten Freyhaus H, Böhm M, Schnabel P, et al. (2011) The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart. Clin Res Cardiol 100(8): 641-7.
19. McLean RC, Baird SW, Becker LC, Townsend SN, Gerstenblith G, et al. (2012) Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors. Am J Cardiol 110(7): 1001-7
20. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, et al. (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74(4): 372-9.
21. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, et al. (2003) A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73(4): 366-71.
22. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, et al. (2009) Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 54(5): 432-44.
23. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al. (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9(10): 1300-5.
24. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, et al. (2005) Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 15(4): 227-34.
25. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103(30): 11288-93.
26. Molenaar P, Chen L, Semmler AB, Parsonage WA, Kaumann AJ (2007) Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34: 1020-8.
27. Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, et al.(2011) Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 71(4):556-65.
28. Liu WN, Fu KL, Gao HY, Shang YY, Wang ZH, et al. (2012) β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis. PLoS One 7(7):e37659.
29. Parvez B, Chopra N, Rowan S, Vaglio JC, Muhammad R, et al. (2012) A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 59(1): 49-56.
30. Rau T, Düngen HD, Edelmann F, Waagstein F, Lainščak M, et al. (2012) Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther 92(1): 21-8.
31. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR (2013) Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol 6(1):137-43.
32. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ (2000) The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 99(3): 233-8.
33. Karlsson J, Lind L, Hallberg P, Michaëlsson K, Kurland L, et al. (2004) Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 27(6): 347-350.
34. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, et al. (2005) The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 7(6): 966-73.
35. Metra M, Covolo L, Pezzali N, Zacà V, Bugatti S, et al. (2010) Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 24(1): 49-60.
36. Davis HM, Johnson JA (2011) Heart failure pharmacogenetics: past, present, and future. Curr Cardiol Rep 13(3):175-84.
37. Petersen M, Andersen JT, Jimenez-Solem E, Broedbaek K, Hjelvang BR, et al. (2012) Effect of the Arg389Gly β1-adrenoceptor polymorphism on plasma renin activity and heart rate, and the genotype-dependent response to metoprolol treatment. Clin Exp Pharmacol Physiol 39(9): 779-85.
38. Granneman JG (2001) The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 280: E199-202.
39. Molenaar P (2003) The 'state' of beta-adrenoceptors. Br J Pharmacol 140: 1-2.
40. Arch JR (2004) Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine? Br J Pharmacol 143: 517-518.
41. Kaumann AJ, Molenaar P (2008) The low-affinity site of the beta1-adrenoceptor and its relevance to cardiovascular pharmacology. Pharmacol Ther 118: 303-336.
42. Konkar AA, Zhu Z Granneman JG (2000) Aryloxypropanolamine and catecholamine ligand interactions with the β1-adrenergic receptor: evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther 294: 923-932.
43. Baker JG, Hall IP, Hill SJ (2003) Agonist actions of "β- blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol 63: 1312-1321.
44. Joseph SS, Lynham JA, Molenaar P, Grace AA, Colledge WH, et al. (2003) Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)- propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors. Naunyn Schmiedebergs Arch Pharmacol 368: 496-503.
45. Baker JG (2005) Sites of action of β-ligands at the human β1-adrenoceptor. J Pharmacol Exp Ther 313: 1163-1171.
46. Baker JG (2010) The selectivity of β-adrenoceptor agonists at the human β1, β2 and b3 adrenoceptors. Br J Pharmacol 160: 1048-1061.
47. Jasper JR, Michel MC, Insel PA (1988) Molecular mechanism of beta-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J 2: 2891-2894.
48. Jasper JR, Michel MC, Insel PA (1990) Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists. Mol Pharmacol 37: 44-49.
49. Baker JG, Hill SJ (2007) A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor. J Pharmacol Exp Ther 320: 218-228.
50. Lowry OH, Rosebrough NJ, Farr AC, Randall RJ (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265-275.
51. 1-receptor to the nucleus. Mol Pharmacol 59: 1012-1021
52. Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol 11: 5109-5116.
53. Walter M, Lemoine H, Kaumann AJ (1984) Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn Schmiedebergs Arch Pharmacol 327: 159-175.
54. Galandrin S, Bouvier M (2006) Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol 70(5): 1575-1584.
55. Small KM, McGraw DW, Liggett SB (2003) Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 43: 381-411.
56. Iredale PA, Hill SJ (1993) Increases in intracellular calcium via activation of an endogenous P2-purinoceptor in cultured CHO-KI cells. Br J Pharmacol 110: 1305-1310
57. Azzi M, Charest PG, Angers S, Rosseau G, Kohout T, et al. (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406-11.
58. 2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol 64: 1357-1369.
59. Baker JG, Hill SJ (2007) Multiple GPCR conformations and signalling pathways: Implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374-381. Council